OIA GLOBAL’s Post

Navigating Canada's pharmaceutical regulations can be overwhelming for businesses, especially those dealing in food products, ingredients, and additives. Two pivotal documents in this regulatory landscape—the Health Canada Drug Monograph and Product Monograph—hold distinct roles and purposes. Understanding these differences is crucial. Read the Guide: https://lnkd.in/gQCVMWjT #compliance #foodmonographs #safety #consumersafety

Navigating Canada's pharmaceutical regulations can be overwhelming for businesses, especially those dealing in food products, ingredients, and additives. Two pivotal documents in this regulatory landscape—the Health Canada Drug Monograph and Product Monograph—hold distinct roles and purposes. Understanding these differences is crucial. Read the Guide: https://lnkd.in/gQCVMWjT #compliance #foodmonographs #safety #consumersafety

Navigating Canada's pharmaceutical regulations can be overwhelming for businesses, especially those dealing in food products, ingredients, and additives. Two pivotal documents in this regulatory landscape—the Health Canada Drug Monograph and Product Monograph—hold distinct roles and purposes. Understanding these differences is crucial. Read the Guide: https://lnkd.in/gQCVMWjT #compliance #foodmonographs #safety #consumersafety

"Thrilled to have attended the #OneDaySymposium on #GMPCompliances Opportunities: On Export and Import’s Regulators' View at #JSSCollegeofPharmacy, Mysuru, on #April6th2024. A comprehensive exploration of crucial industry standards and regulatory perspectives, fostering invaluable insights for navigating global markets. Grateful for the opportunity to enhance my understanding of regulatory frameworks and trade dynamics in the pharmaceutical sector." #Importexport #GMPcompliance #Regulatorydevelopment

Yesterday, I had the opportunity to share our views on the root causes of Europe's dependency on APIs manufactured outside Europe (mainly for off-patent drugs) at the SANT Committee hearing on over reliance on imported APIs. We discussed key challenges such as price pressure and rising costs, which frequently drive to loss-making drugs and provoke shortages. More importantly, we explored potential solutions: creating a supportive industrial framework for API manufacturing in Europe and adopting market policies that go beyond a sole focus on (low price). The proposals Medicines for Europe is advocating to be included in the upcoming #CriticalMedicinesAct, which help #criticalmedicines and #APIs and other many widely used medicines. Ensuring a resilient and sustainable pharmaceutical supply chain in Europe requires decisive action. Let's move!!! Thank you to SICOS (chimie fine & biotech) and EFCG - European Fine Chemicals Group for sharing relevant data for this hearing. #medicinesforeurope #criticalmedicinesact #APIs #genericdrugs #europe

India has raised the issue of pharmaceutical pricing control in Australia, particularly on generic medicines, during a recent bilateral meeting between the officials of the two countries. The two sides have decided to work closely on timely resolution of market access issues, deepen people-to-people contacts, and create an institutional mechanism for sharing of preferential import data, the commerce ministry said on Saturday. These issues among others were discussed during the first Joint Committee Meeting (JCM) in Canberra under India-Australia Economic Co-operation and Trade Agreement. #import #export #globaltrade

India has raised the issue of pharmaceutical pricing control in Australia, particularly on generic medicines, during a recent bilateral meeting between the officials of the two countries. The two sides have decided to work closely on timely resolution of market access issues, deepen people-to-people contacts, and create an institutional mechanism for sharing of preferential import data, the commerce ministry said on Saturday. These issues among others were discussed during the first Joint Committee Meeting (JCM) in Canberra under India-Australia Economic Co-operation and Trade Agreement. #import #export #globaltrade

Day 1 at the 10th Pharma Supply Chain & Logistics Innovation Programme in Basel highlighted several critical issues, including counterfeit medicines and sustainability. GS1 reports that over one million lives are lost annually due to counterfeit drugs, with up to 30% of medicines in some regions being fake. Among the many steps to prevent counterfeit, substandard, and falsified medicines, Bonafi focuses on the very first step: helping pharma companies know who they are selling medicinal products to and who they are buying them from. We ensure robust customer and supplier qualification to reduce risk, improve compliance and greatly improve efficiencies. Be sure to contact me if you'd like to know more! #PharmaSupplyChain #CounterfeitDrugs #PatientSafety #Compliance #Bonafi

The USAID-funded PQM+ program is partnering with Rwanda Medical Supply Ltd, a public pharmaceutical procuring agency for health commodities, to provide technical support to implement a robust Quality Management System, and help the organization achieve ISO 9001:2015 certification. These efforts will enhance the credibility and reputation of RMS Ltd on the global market and help to ensure the quality of medicines in #Rwanda. #HealthSystems

🤝 Cefic supports the call for stronger EU measures to address critical medicine shortages across Europe. Through our Sector Group, EFCG - European Fine Chemicals Group (EFCG), we have joined the Critical Medicines Alliance which aims to strengthen supplies of critical medicines in Europe. 🌍 💊 Active Pharmaceutical Ingredients (APIs) and their fine chemicals precursors are the building blocks on which all critical medicines are based. Yet over the past 25 years, Europe’s share of APIs has halved. 📉   On joining the Alliance, Maggie Saykali, Cefic’s Director Specialty Chemicals, said:   “We can provide important insights on the key value chain players, capacities in Europe, technologies involved in the manufacturing process, among others. Our goal is to strengthen Europe’s strategic autonomy and re-establish Europe as a major player in API manufacturing.”   EFCG has outlined recommendations to achieve a resilient medicine supply chain in Europe, including fostering supportive legislative policies for EU API manufacturers, emphasising sustainable growth and reshoring initiatives, while investing in innovation and shifting procurement focus towards supply security and social-environmental standards. (https://lnkd.in/e9X2QYz2) 🔗 https://lnkd.in/eMi8Fa2q #CriticalMedicines #StrategicAutonomy